Sellas, Life

Sellas Life Sciences: A Phase III Survival Win, a Priced Share Sale, and the Dilution Arithmetic In Between

Published on 11/21/2026 at 04:11 | Editorial boerse-global.de
Sellas closed its $13.00-per-share equity placement, raising $172.5M gross, after Phase III REGAL data showed 24.0-month median OS for GPS in AML.
Sellas Life Sciences Illustration mit AI erstellt.

Sellas Life Sciences closed its equity placement on Thursday, including the full exercise of the underwriters' over-allotment option, a move that has reshaped the share count just as the company's clinical story gathered momentum. The offering, priced at $13.00 per share, generated gross proceeds of $172.5 million, with net proceeds expected to reach roughly $161.8 million after underwriting discounts, commissions and estimated expenses. The banks exercised the option in full — up to 1,730,769 additional shares — and the company expects the placement to settle on or around today, subject to customary conditions.

The financing follows hard on the heels of positive Phase III REGAL data for galinpepimut-S (GPS) in acute myeloid leukemia, reported Tuesday. The trial hit its primary endpoint on overall survival: median OS came in at 24.0 months on GPS versus 14.7 months on the best available treatment. Sellas put the reduction in death risk at 41%, with a hazard ratio of 0.59 and a p-value of 0.035. Those numbers are the substantive counterweight to the dilution — a larger share count does not erase the reported trial result, and a hit endpoint does not make the economics of a capital raise irrelevant.

Two Verdicts on One Ticker

The stock's reaction tells the story of two yardsticks meeting at once. Shares fell 8.1% on Friday, with media reports attributing the selling pressure to the discounted placement rather than to the REGAL readout itself. A separate reading of the tape put the decline at 7.4% to €12.55. Either way, the distinction matters: a clinical success and the financing that pays for it are not the same news for shareholders. The trial supplies the argument for the drug; the new shares change each existing owner's slice of whatever that drug eventually earns.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

It would be too simple to read the pullback as a verdict on the medical results. Fresh equity strengthens the company's financing runway while spreading its future upside across more shares — both things can be true at once. The tension between research and financing is the more useful lens here than the color of the tape.

From Data to Filing

What comes next is regulatory. Sellas said Tuesday it intends to hold talks with the FDA and push ahead with preparations for a BLA submission. Those are announced intentions, not a filed application or an agency decision. Over the coming sessions, the more meaningful signal will be concrete progress on the FDA discussions and the application build — a better gauge of the operating story than any single day's move.

For now the picture is a company with a reported survival benefit in hand, a strengthened balance sheet, and a larger share count. How Sellas converts the REGAL result into the next regulatory step is where the story goes from here.

Ad

Sellas Life Sciences Stock: New Analysis - 21 November

Fresh Sellas Life Sciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Sellas Life Sciences analysis...

Disclaimer...
en | US81642T2096 | SELLAS | boerse | 70541318 |